
News|Articles|October 1, 2025
7 Pulmonology Headlines You Missed in September 2025
Author(s)Victoria Johnson
Fact checked by: Tim Smith
September 2025 saw 1 new approval, new long term data on smoking and emphysema, and more.
Advertisement
Advertisement
September 2025 brought a mix of advances and setbacks in pulmonology, with new clinical trial readouts and regulatory updates highlighting the evolving landscape of respiratory care. Landmark data in idiopathic pulmonary fibrosis, sarcoidosis, and emphysema underscored both the promise of novel therapies and the ongoing challenges of treating progressive lung disease. At the same time, large-scale studies shed light on the intergenerational effects of smoke exposure, reinforcing the long-term importance of preventive measures in public health.
Related to this article

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Juanita Mora, MD, of Chicago Allergy Center discusses strategies from boosters and antiviral prophylaxis to specialist counseling.

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
Advertisement
Advertisement

